Contributions
Abstract: P1149
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - OCT
Background: Prior studies have demonstrated the usefulness of optical coherence tomography (OCT)-derived retinal nerve fiber layer (RNFL) in prediction of the risk for disability worsening in multiple sclerosis (MS) patients.
Objective: To determine if 5-year RNFL change can identify patients with disability progression within an age-specific (younger vs. aging) MS population.
Methods: The study utilized OCT-derived RNFL measurements of 138 MS patients and 271 eyes over the follow-up period of 5-years. The examination failed in 5 eyes either at baseline or at follow-up visit. Patients were classified into two age groups based on their age at study entry (below and above 55 years old). Disability progression (DP) was classified as an Expanded Disability Status Scale (EDSS) increase of ≥1.0 if baseline EDSS was 1.0-5.5 and EDSS increase of ≥0.5 if baseline EDSS was ≥5.5. Absolute and percent RNFL change were calculated and shown. Repeated-measure (rm) Wilcoxon test and Student's t-test were used. A p-value lower than 0.05 was considered statistically significant.
Results: The overall MS patient group demonstrated significant RNFL decrease over the follow-up period (mean absolute change of 3.1µm (4.2%), rm-p< 0.001). Within age-specific groups, both MS patients under and over age 55 demonstrated a similar significant RNFL decrease (longitudinal rm p< 0.001 for both groups; between groups 3.1µm (4.3%) vs. 3.0µm (4.2%), p=0.935). All four individual groups (DP/stable below 55 and DP/stable above 55) showed a significant RNFL decrease (rm p< 0.001) as well. Aging DP patients demonstrated a trend for a larger RNFL decrease when compared their stable counterparts (5.1µm [7.6%] vs. 2.1µm [2.7%], p=0.062), whereas this difference was not significant between younger DP and their stable counterparts (3.7µm [5.7%] vs. 2.8µm [3.7%], p=0.429).
Conclusion: The RNFL change over 5-year period continues to decline despite the different age and DP status of the MS patients. MS patients that experience DP, especially aging patients, may have an accelerated RNFL atrophy trajectory.
Disclosure: Caila B Vaughn has served as a consultant for Merck/EMD Serono.
Robert Zivadinov has received personal compensation from EMD Serono, Genzyme-Sanofi, Claret Medical, IMS Health, Celgene, Roche-Genentech and Novartis for speaking and consultant fees. He has received financial support for research activities from Genzyme-Sanofi, Novartis, Claret Medical, Intekrin and IMS Health
Bianca Weinstock-Guttman has received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme & Sanofi, Novarties and Acorda. Dr. Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme & Sanofi , Novartis and Acorda.
The remaining authors have nothing to disclose.
This study was supported in part by Biogen Idec (IIS Aging - PI: Dr. Weinstock-Guttman)
Abstract: P1149
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - OCT
Background: Prior studies have demonstrated the usefulness of optical coherence tomography (OCT)-derived retinal nerve fiber layer (RNFL) in prediction of the risk for disability worsening in multiple sclerosis (MS) patients.
Objective: To determine if 5-year RNFL change can identify patients with disability progression within an age-specific (younger vs. aging) MS population.
Methods: The study utilized OCT-derived RNFL measurements of 138 MS patients and 271 eyes over the follow-up period of 5-years. The examination failed in 5 eyes either at baseline or at follow-up visit. Patients were classified into two age groups based on their age at study entry (below and above 55 years old). Disability progression (DP) was classified as an Expanded Disability Status Scale (EDSS) increase of ≥1.0 if baseline EDSS was 1.0-5.5 and EDSS increase of ≥0.5 if baseline EDSS was ≥5.5. Absolute and percent RNFL change were calculated and shown. Repeated-measure (rm) Wilcoxon test and Student's t-test were used. A p-value lower than 0.05 was considered statistically significant.
Results: The overall MS patient group demonstrated significant RNFL decrease over the follow-up period (mean absolute change of 3.1µm (4.2%), rm-p< 0.001). Within age-specific groups, both MS patients under and over age 55 demonstrated a similar significant RNFL decrease (longitudinal rm p< 0.001 for both groups; between groups 3.1µm (4.3%) vs. 3.0µm (4.2%), p=0.935). All four individual groups (DP/stable below 55 and DP/stable above 55) showed a significant RNFL decrease (rm p< 0.001) as well. Aging DP patients demonstrated a trend for a larger RNFL decrease when compared their stable counterparts (5.1µm [7.6%] vs. 2.1µm [2.7%], p=0.062), whereas this difference was not significant between younger DP and their stable counterparts (3.7µm [5.7%] vs. 2.8µm [3.7%], p=0.429).
Conclusion: The RNFL change over 5-year period continues to decline despite the different age and DP status of the MS patients. MS patients that experience DP, especially aging patients, may have an accelerated RNFL atrophy trajectory.
Disclosure: Caila B Vaughn has served as a consultant for Merck/EMD Serono.
Robert Zivadinov has received personal compensation from EMD Serono, Genzyme-Sanofi, Claret Medical, IMS Health, Celgene, Roche-Genentech and Novartis for speaking and consultant fees. He has received financial support for research activities from Genzyme-Sanofi, Novartis, Claret Medical, Intekrin and IMS Health
Bianca Weinstock-Guttman has received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme & Sanofi, Novarties and Acorda. Dr. Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme & Sanofi , Novartis and Acorda.
The remaining authors have nothing to disclose.
This study was supported in part by Biogen Idec (IIS Aging - PI: Dr. Weinstock-Guttman)